NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Denali Therapeutics

Denali Therapeutics

Public
South San Francisco, CaliforniaBiotechhttps://www.denalitherapeutics.com/

Denali Therapeutics is now publicly traded

The data on this page reflects Denali Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Went Public

Dec 7, 2017

Last Round

Follow-on Offering

Dec 10, 2025

Total Funding Raised

$1.61B

Company Overview

Denali Therapeutics is a biotechnology company that discovers and develops innovative biotherapeutics designed to cross the blood-brain barrier for the treatment of neurodegenerative and lysosomal storage diseases.

Sector

Biotech

AI Layer

Non-AI

Keywords

biopharmaceuticalblood-brain barrierneurodegenerative diseasedrug delivery platformtransport vehicle technologyTV platformBBB deliveryCNS therapeuticsbiotech pipelineenzyme replacement therapykinase inhibitorclinical-stage biotechlysosomal storage diseasedrug licensingbiotech pharma partner

Denali Therapeutics Comparables

Compare Denali Therapeutics with similar companies based on industry and business-model similarity.

Denali Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

Denali Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Follow-on OfferingDec 10, 2025
StrategicDec 4, 2025
PIPEFeb 27, 2024
IPODec 7, 2017
Series BAug 25, 2016
Series A
May 14, 2015

Key People

Founding team and executive leadership

Ryan Watts

CEO

Executive Team

Denali Therapeutics Investors

Notable investors and investment history

Denali Therapeutics investors
InvestorRounds
Morgan Stanley & Co., LLCFollow-on Offering
F-Prime CapitalSeries B, Series A
Biomatics Capital PartnersSeries A
Morgan StanleyIPO
ARCH Venture PartnersSeries B, Series A
Royalty PharmaStrategic
Goldman Sachs & Co. LLCIPO, Follow-on Offering

Denali Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Denali Therapeutics Filings

SEC and related filings with document metadata.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range565
Year Founded2015
Last FundingDec 10, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.